Markers of inflammation and fibrinolysis in canine lymphoma

Canine lymphoma is one of the most common haematological neoplasms. Results of a numerous studies indicate the important role of chronic inflammation in the development of cancer. The aim of this study was to determine the concentrations of novel inflammatory biomarkers in canine lymphoma. Fifteen dogs with lymphoma and 15 healthy dogs (control group) participated in this study. The plasma levels of high sensitivity C reactive protein (hs CRP), interleukin-6 (IL-6), high mobility group box-1 (HMGB-1), soluble intercellular adhesive molecule -1 (sICAM-1), plasminogen activator inhibitor -1 (PAI-1) and soluble urokinase receptor of plasminogen activator (suPAR) were measured using canine specific enzyme-linked immunosorbent assay (ELISA). Lactate dehydrogenase activity (LDH) was measured using a spectrophotometric method. Dogs with lymphoma had significantly increased plasma hsCRP, IL-6, HMBG-1, slCAM-1, and LDH compared with the control group. In addition. hsCRP, IL-6, HMBG-1, and suPAR concentrations and LDH activity showed a significant strong positive correlation in the lymphoma group. The data obtained support the role of cytokine-mediated inflammation in canine lymphoma, and suggest the possibility that anti-inflammatory therapies might provide a supportive effect. The significant and strong positive correlation between the established (hsCRP, IL-6) and novel (HMGB-1, suPAR) inflammatory biomarkers indicate their potential usefulness in canine lymphoma diagnostics.